BCR engagement on CLL cells induces increased expression of these molecules (9) and it is therefore not surprising that BTK-inhibition by ibrutinib affects tumor cells-TME cells interactions, e.g. impairing CXCR4 signaling and therefore inhibiting cellular adhesion (18, 19). The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.